- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-IRF3
IRF3 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain et plus (5)
Applications
WB, IHC, IF/ICC, IP, CoIP, ChIP, RIP, ELISA
Conjugaison
Non conjugué
N° de cat : 11312-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules HEK-293T, cellules HCT 116, cellules HeLa, cellules Jurkat, cellules MCF-7, cellules MDA-MB-231 |
| Résultats positifs en IP | cellules Jurkat |
| Résultats positifs en IHC | tissu d'amygdalite humain, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
| Résultats positifs en IF/ICC | cellules HeLa, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochimie (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Informations sur le produit
11312-1-AP cible IRF3 dans les applications de WB, IHC, IF/ICC, IP, CoIP, ChIP, RIP, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | rat, bovin, Humain, porc, singe, Hamster |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | IRF3 Protéine recombinante Ag1858 |
| Nom complet | interferon regulatory factor 3 |
| Masse moléculaire calculée | 47 kDa |
| Poids moléculaire observé | 50-60 kDa |
| Numéro d’acquisition GenBank | BC009395 |
| Symbole du gène | IRF3 |
| Identification du gène (NCBI) | 3661 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
The virul-induced expression of interferon(IFN) genes in infected cells implicate in the interplay of several constitutively expressed and virus-activated transcription factors. A family of IFN regulatory factors(IRFs) have been shown to has a role in the transcription of IFN genes as well as IFN-stimulated genes. IRF3 is a novel key transcriptional regulator of type I IFN-dependent immune responses and involves in the innate immune response against DNA and RNA viruses, by binding to the promoters of IFN. It located in the cytoplasm of uninfected cells in an inactive form, and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, could be phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization, nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. IRF3 exists some isoforms with MV 47-49 kDa, 33 kDa and 12-16 kDa.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for IRF3 antibody 11312-1-AP | Download protocol |
| IHC protocol for IRF3 antibody 11312-1-AP | Download protocol |
| IF protocol for IRF3 antibody 11312-1-AP | Download protocol |
| IP protocol for IRF3 antibody 11312-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Mol Cancer YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment | ||
Mol Cell An Epstein-Barr virus protein interaction map reveals NLRP3 inflammasome evasion via MAVS UFMylation | ||
Adv Sci (Weinh) Mitigating Doxorubicin-Induced Cardiotoxicity and Enhancing Anti-Tumor Efficacy with a Metformin-Integrated Self-Assembled Nanomedicine | ||
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH Sarah (Verified Customer) (12-18-2019) | This antibody is awesome- been searching for an Pab IRF 3 antibody that works well in a species other than human, and we finally found this one! Thank you!
|





